GEN News Highlights

SAFC, CatScI Team Up to Offer Catalysis Services

(Page
1
of
1)

SAFC Commercial, Sigma-Aldrich's custom manufacturing services business unit, is now in a services agreement with U.K.-based catalysis company CatScI. SAFC says that their customers will now have access to new reactions, homogeneous and heterogeneous catalysis, biocatalysts, solvent selection and process development, in addition to metal removal, recovery and recycling services as a result of the new agreement.

“As a combined offering, we are able to provide customers a single source for high-quality, high-value fundamental research, development, scale-up and manufacture, with additional process development resources for customers to screen projects more quickly, and efficiently maximize catalyst reactions using the appropriate ligands, solvents, and science,” said Andreas Weiler, head of Global Strategic Marketing for Contract Manufacturing Services & Solutions at SAFC, in a statement.

Formed in late 2010, CatScI's facility in Cardiff was set up in 2011 after the company purchased 16 tons of scientific equipment following the reorganization of R&D within AstraZeneca and the closing of the research laboratories at Avlon. Back in April, they entered into a partnership agreement with SiliCycle to support the Canadian firm's development of supported catalysts and scavengers and to act as an agent for the company. SiliCycle develops, manufactures, and commercializes silica-based and specialty products for chromatography, analytical and organic chemistry.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.